Integrated Prognostic Score in Metastatic Castration-resistant Prostate Cancer Treated with Cabazitaxel – A CABASTY Post Hoc Analysis Validated by Two International Prospective Phase 3 Trials

Key Points

• To assess the prognostic score in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel.
• Conducted post hoc analysis of CABASTY trial and validated with PROSELICA and CARD trials.
• Utilized data from international prospective phase 3 trials to compare treatment outcomes.
• Analyzed survival rates related to the integrated prognostic score.
• Demonstrated a significant correlation between the prognostic score and patient survival.
• Identified improved treatment outcomes in patients with higher prognostic scores.